Continuous Processing Potential Outside of Traditional Small Molecule & Monoclonal Antibody Applications
Time: 1:05 pm
day: Stream 2 - Day 2
Details:
• What technologies are available for cell, gene, and vaccine continuous manufacturing?
• How close are these technologies to commercialization? – How easy are commercially available technologies able to be adapted to process needs?
• What are the drivers for exploring CM for modalities outside of the traditional small molecules & monoclonal antibodies?
Speakers:
Martin D. Johnson works for Eli Lilly and Company in Small Molecule Design and Development. He received his dual doctorate in chemical engineering and environmental engineering from the University of Michigan in 2000, and his undergraduate in Chemical Engineering from Virginia Tech. Prior to joining Eli Lilly in 2005, he worked as a process research…Read more
Dr Michael West has a PhD in Chemistry from James Cook University, an MIP from University of Technology Sydney and professional management qualifications. Michael has been successful in translating technology challenges in both human and animal health over a 30 year period. Michael joined Exopharm in 2021 and brings an extensive technical, commercial and entrepreneurial…Read more
